文献速递脑血管病

无适应证脑缺血患者中的他汀过度使用:系统综述及美国年度不良事件负担

Statin Overuse in Cerebral Ischemia Without Indications: Systematic Review and Annual US Burden of Adverse Events.
PubMed 文献 · Stroke · 2024-06-14

该系统综述与Meta分析评估了无他汀适应证的急性脑缺血(ACI)患者中他汀过度使用的不良事件负担。基于63项随机临床试验(155107例)和55项大型系列(53501例),他汀治疗与糖尿病、肌痛或肌无力、肌病、肝病、肾功能不全和眼病风险增加相关;美国每年约5601例无适应证患者因过度使用他汀发生不必要的不良事件。

要点

  • 超过五分之一的ACI患者无他汀适应证,美国每年因此类过度使用导致超过5600例不良事件。
  • 他汀治疗与糖尿病、肌痛或肌无力、肌病、肝病、肾功能不全和眼病风险增加相关。
  • 指南推荐他汀用于大或小血管动脉粥样硬化性ACI,或无此机制但合并冠心病或一级预防适应证者。

核心结论

  • 超过五分之一的ACI患者无他汀适应证,此类过度使用在美国每年可导致超过5600例不良事件,包括糖尿病、肌病和眼病。
  • 这些发现强调在ACI中启动他汀治疗时应遵循指南适应证的重要性。

研究设计与样本

  • 遵循系统综述和Meta分析首选报告条目(PRISMA)指南,进行系统Meta分析。
  • 分析包括:63项他汀随机临床试验(155107例)用于确定6种主要不良事件的绝对风险增加;55项大型系列(53501例)用于确定大或小血管动脉粥样硬化性ACI事件比例及剩余患者中冠心病/一级预防他汀适应证比例。

主要发现

  • 他汀治疗与6种情况发生风险增加相关:糖尿病、肌痛或肌无力、肌病、肝病、肾功能不全和眼病。
  • 55项大型系列(53501例)中,大动脉和小动脉粥样硬化所致ACI率为45.0%(大动脉粥样硬化21.6%,小血管病23.4%)。
  • 剩余患者中冠心病/一级预防他汀适应证率为31.8%,无他汀适应证率为23.2%。
  • 数据合成表明,若美国所有无他汀适应证的ACI患者均接受他汀治疗,每年共5601例患者将发生不必要的不良事件,最常见为糖尿病、肌病和眼病。

关键数值与推荐

  • 国家指南推荐他汀用于大或小血管动脉粥样硬化起源的ACI患者,以及无这些卒中机制但合并冠心病或一级预防适应证的患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Statin agents play a major role in secondary prevention after acute cerebral ischemia (ACI) events but are not indicated in all patients with ischemic stroke and transient ischemic attack. National guidelines recommend statins for patients with ACI of large or small vessel atherosclerotic origin and without these stroke mechanisms but coexisting coronary artery disease or primary prevention indications. The potential adverse effect burden of statin overuse in the remaining ACI patients have not been well delineated. METHODS: Per Preferred Reporting Items of Systematic Reviews and Meta-Analyses guidelines, we performed systematic meta-analyses of: (1) statin randomized clinical trials to determine absolute risk increases for 6 major adverse events; (2) large clinical series to determine the proportion of ACI events due to large or small vessel atherosclerotic disease; and (3) the proportion of remaining patients with coronary artery disease/primary prevention statin indications. RESULTS: For adverse effects, data were available from 63 randomized clinical trials enrolling 155 107 patients. Statin therapy was associated with an increased risk of the occurrence of 6 conditions: diabetes, myalgia or muscle weakness, myopathy, liver disease, renal insufficiency, and eye disease. Across 55 large series enrolling 53 501 patients, the rate of ACI due to large and small artery atherosclerosis was 45.0% (large artery atherosclerosis 21.6%, small vessel disease 23.4%), the rate of remaining patients with coronary artery disease/primary prevention statin indications was 31.8%, and the rate of patients without statin indications was 23.2%. Data synthesis indicated that, in the United States, were all patients with ACI without statin indications treated with statins, a total of 5601 patients would develop needless adverse events each year, most commonly diabetes, myopathy, and eye disease. CONCLUSIONS: More than one-fifth of patients with ACI do not have an indication for statins, and statin overuse in these patients could annually lead to over 5600 adverse events each year in the United States, including diabetes, myopathy, and eye disease. These findings emphasize the importance of adhering to guideline indications for the start of statin therapy in ACI.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Sung EM, Saver JL. Statin Overuse in Cerebral Ischemia Without Indications: Systematic Review and Annual US Burden of Adverse Events. Stroke. 2024. PMID: 38873773. doi:10.1161/STROKEAHA.123.044071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。